Table 3.
Effects of PAßN treatment on virulence phenotypes in P. aeruginosa clinical isolates.
| Straina | 3OC12-HSLb | Pyocyaninb | Swarming motilityb |
|---|---|---|---|
| AA2 | 102% | 86% | <10% |
| AA11 | NP | 125% | NS |
| AA12 | 24% | 73% | NS |
| AA43 | NP | NP | <10% |
| AA44 | 59% | 142% | <10% |
| KK2 | 74% | NP | NS |
| KK27 | 81% | NP | NS |
| KK71 | 97% | NP | NS |
| KK72 | 134% | NP | NS |
| TR1 | NP | NP | <10% |
| TR66 | NP | NP | <10% |
a P. aeruginosa strains isolated from cystic fibrosis patients47.
bPercentage of 3OC12-HSL levels, pyocyanin production or swarming motility in the presence of 27 µM PAßN with respect to the untreated control. The average of at least three independent experiments is reported; SD ≤ 10%. NP, non producer strain; NS, non swarmer strain.